Home / Companies / Karyopharm Therapeutics Inc. / 28 May 2025
Karyopharm Therapeutics Inc.: meeting of 28 May 2025
Votes reported on Form N-PX, item by item
90 Form N-PX filers reported votes at the Karyopharm Therapeutics Inc. meeting of 28 May 2025. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 92.6% of reported votes for; 4 filers withheld from or voted against at least one nominee.
54 vote records from 20 filers. 0 of the 20 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
104 vote records from 87 filers. 8 of the 80 filers that marked the item either way voted against management. 7 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Frequency of the say-on-pay vote
one year: 76 filers; three years: 2 filers; 1-year: 1 filer; for: 1 filer.
101 vote records from 86 filers. 3 of the 80 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
27 vote records from 20 filers. 1 of the 20 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
30 vote records from 22 filers. 0 of the 22 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|---|
| Vanguard | For | For | Split or no vote | For |
| BlackRock and iShares | For | For | Split or no vote | For |
| Fidelity | For | For | Split or no vote | For |
| State Street and SPDR | No report | For | Split or no vote | No report |
| Equitable | For | For | Split or no vote | For |
| Charles Schwab | For | For | Split or no vote | For |
| John Hancock and Manulife | For | For | Split or no vote | For |
| Morgan Stanley, Eaton Vance and Calvert | No report | For | Split or no vote | No report |
| Goldman Sachs | For | For | Split or no vote | For |
| Northern Trust and FlexShares | No report | For | Split or no vote | No report |
| SEI | No report | For | Split or no vote | No report |
| T. Rowe Price | For | For | Split or no vote | For |
| BNY Mellon | No report | For | Split or no vote | No report |
| MassMutual | Split or no vote | For | Split or no vote | For |
| Macquarie and Delaware Funds | Split or no vote | For | Split or no vote | For |
| Baird | No report | For | Split or no vote | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Karyopharm Therapeutics Inc. meeting?
90 Form N-PX filers reported votes at the meeting of 28 May 2025. On say-on-pay, 8 of 80 voted against management (10.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Karyopharm Therapeutics Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Karyopharm Therapeutics Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Karyopharm Therapeutics Inc. with a meeting date within three days of 28 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.